Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 54 of the 54 references it cites were found in a registry or an index; 18 of the 61 sources its claims cite were checked for support.
Abstract
Mitochondrial complex II is a tumor suppressor comprised of four subunits (SdhA, SdhB, SdhC, and SdhD). Mutations in any of these should disrupt complex II enzymatic activity, yet defects in SdhA produce bioenergetic deficiency while defects in SdhB, SdhC, or SdhD induce tumor formation. The mechanisms underlying these differences are not known. We show that the inhibition of distal subunits of complex II, either pharmacologically or via RNA interference of SdhB, increases normoxic reactive oxygen species (ROS) production, increases hypoxia-inducible factor alpha (HIF-alpha) stabilization in an ROS-dependent manner, and increases growth rates in vitro and in vivo without affecting hypoxia-mediated activation of HIF-alpha. Proximal pharmacologic inhibition or RNA interference of complex II at SdhA, however, does not increase normoxic ROS production or HIF-alpha stabilization and results in decreased growth rates in vitro and in vivo. Furthermore, the enhanced growth rates resulting from SdhB suppression are inhibited by the suppression of HIF-1alpha and/or HIF-2alpha, indicating that the mechanism of SdhB-induced tumor formation relies upon ROS production and subsequent HIF-alpha activation. Therefore, differences in ROS production, HIF proliferation, and cell proliferation contribute to the differences in tumor phenotype in cells lacking SdhB as opposed to those lacking SdhA.
Overview
CoChat Summary
TL;DR
In multiple tumor cell lines and xenografts, suppressing the distal complex II subunit SdhB increased normoxic ROS and HIF-1α/HIF-2α stabilization, enhanced proliferation and tumor growth, whereas suppressing proximal SdhA did not increase ROS/HIF and reduced growth. The SdhB-driven growth phenotype required HIF-1α and/or HIF-2α, supporting an ROS-dependent pseudohypoxic mechanism for SdhB/C/D-linked tumorigenesis.
Key findings
- Pharmacologic inhibition at SdhD with TTFA (200 µM) increased normoxic HIF-1α, HRE-luciferase activity, and ROS (roGFP, DHE, Mito-SOX); SdhA inhibitors 3-NPA (100 µM) and MMA (1 mM) did not, and blocked TTFA-induced HIF-1α stabilization.
- Stable SdhB shRNA in 143B, A549, and Hep3B cells reduced complex II activity and increased normoxic HIF-1α/HIF-2α, VEGF mRNA, HRE-luciferase, and ROS; HIF stabilization was attenuated by ebselen (25 µM), Mito-Q (1 µM), or 3-NPA (100 µM).
- SdhA shRNA reduced complex II activity but did not significantly increase normoxic HIF-1α or ROS and decreased in vitro growth; SdhB shRNA increased in vitro growth and xenograft tumor growth/mass, while SdhA shRNA tumors grew more slowly than wild-type or SdhB shRNA tumors.
- In SdhB shRNA 143B cells, suppressing HIF-1α and/or HIF-2α significantly decreased in vitro growth, tumor growth, and tumor mass compared with dHIF control.
Methods
- Used Hep3B, A549, and 143B cells with stable shRNA against SdhB or SdhA, plus retroviral HIF-1α/HIF-2α shRNA in SdhB shRNA 143B cells; pharmacologic agents included TTFA, 3-NPA, MA, MMA, DMS, ebselen, Mito-Q, and TBAP.
- Measured complex II activity, HIF-1α/HIF-2α/VEGF by immunoblot, HRE-luciferase, ROS by roGFP, DHE, and Mito-SOX, in vitro growth, and nude mouse xenografts (1 × 10⁶ cells; monitored 25–35 days).
- Compared results to wild-type/mock controls; densitometry and P < 0.05 significance were used.
Limitations
- The paper states it cannot rule out that HIF accumulation with SdhD deficiency proceeds by a different mechanism than SdhB suppression, and that the results do not refute ROS production at SdhD via SdhB/C/D mutations.
- The paper notes the H₂O₂-mediated succinate accumulation model is not inconsistent, but required high H₂O₂ (100–500 µM) and it is unclear whether such levels occur in mitochondria.
- Evident from the text: findings rely on shRNA knockdown and pharmacologic inhibitors in three cell lines rather than patient-derived Sdh mutations, and no direct succinate measurements are reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 22 Not checked · 84 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We previously reported that mitochondrial reactive oxygen species (ROS) signals arising from complex III trigger HIF-1 𝛂 stabilization during hypoxia (10, 21, 31).”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
Our copy of Chandel et al. (1998) supports the mitochondrial/complex III part: 'Our results show that ROS generation at complex III is required for the induction of HIF-1 DNA binding activity during hypoxia' (Results and Discussion), and 'mitochondrial complex III acts as a principal site of ROS generation during hypoxia.' However, the endpoint the paper demonstrates is HIF-1 DNA-binding activity (gel shift) and downstream EPO/VEFG/glycolytic mRNA, not HIF-1α protein stabilization — the paper attributes stabilization to others ('hypoxic stabilization of the HIF-1 complex is related to the O2 concentration (31)', and Caro and Salceda (28) for lactacystin-induced stabilization). The claim's causal 'trigger' also outruns the paper's explicit hedge: 'Our model proposes only that ROS are required for the hypoxic activation of HIF-1, but it is not yet clear whether ROS are sufficient,' with ROS generators (antimycin, menadione) failing to elicit HIF-1 stabilization during normoxia. (LLM, conf=0.78)
- Not checked yetcites [21] source
- Not checked yetcites [31] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An impairment in the normal removal of electrons from the flavin group in SdhA could promote superoxide generation through the autoxidation of the reduced flavin group by O 2 in the matrix (34, 38, 46, 51).”
What the sources say
- Partly supportedcites [34] sourceExperimental — accuracy not yet measured
Our copy supports the mechanistic core: the flavin is the autoxidizing site in Sdh/Frd ('Flavin as the Site of Autoxidation'), Sdh 'makes only O2.-, and no H2O2, upon flavin autoxidation' (Succinate Dehydrogenase Makes Only Superoxide..., Fig. 9), and 'the relative preference of electrons to sit on the flavin is a major determinant of their tendency to autoxidize,' with Sdh's cofactor potentials 'arranged to withdraw electrons away from the flavin,' which 'may largely explain its comparatively low rate of autoxidation' — i.e. electrons retained on the flavin raise superoxide formation. Not supported by this paper: the specific counterfactual about an 'impairment in the normal removal of electrons from the flavin group in SdhA' (our copy names Sdh/FrdA mutants such as FrdA H44C and FrdB C62S, never an SdhA lesion), and the mitochondrial 'matrix' location — the work was done in E. coli inverted membrane vesicles with no reference to a matrix. (LLM, conf=0.75)
- Partly supportedcites [38] sourceExperimental — accuracy not yet measured
The Fig. 2 legend embedded in Section 3 ('Mutations in SDH B encoding the Ip subunit') does support the core idea for the SDH (Fp/Ip) subunits, including SdhA: 'some particular mutation could still favor an over-reduction of a given SDH component (e.g. flavin), resulting in superoxide production', and Section 5 adds that CII (SDH?) 'is a privileged location for superoxide production'. However, our copy nowhere states the specific mechanism the claim attributes — autoxidation of the reduced flavin by O2 — nor localises it to the matrix side (Fig. 1's legend only describes semi-quinone feeding electrons to the UQ pool). Searches for 'autoxidation', 'reduced flavin + O2' and 'matrix' returned no supporting passage, so the mechanistic detail likely rests on the sentence's other citations (34, 38, 46, 51) rather than this paper. (LLM, conf=0.72)
- Partly supportedcites [46] sourceExperimental — accuracy not yet measured
Our copy supports the general premise — that impaired electron flow through complex II can raise superoxide production — with the DISCUSSION passage speculating that 'the complex II defect could affect electron flow such that there is a probable increase of electrons leaking directly from complex II to molecular oxygen,' and the Abstract identifying SDHA/Fp as the flavoprotein subunit. However, the paper never attributes superoxide generation to autoxidation of the reduced flavin group of SdhA by matrix O2; its specific proposed mechanism is premature release of semiquinone at the ubiquinone-binding site of Cyt-1/ceSDHC (residue 71, the mev-1 mutation), DISCUSSION. The flavin-autoxidation element of the claim is therefore absent from this source. (LLM, conf=0.72)
- Not checked yetcites [51] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Complex II oxidizes succinate to fumarate and transfers the electrons to ubiquinone through a sequence of steps involving a flavin moiety in SdhA, a set of iron-sulfur clusters in SdhB, a heme group in SdhC, and the ubiquinone binding site in SdhC and SdhD (Fig. 1) (1, 9).”
What the sources say
- Partly supportedcites [1] Ackrell B. A. C., 2000, FEBS Lett. sourceExperimental — accuracy not yet measured
The Introduction says complex II oxidizes succinate to fumarate and transfers electrons to ubiquinone; it also places FAD in the flavoprotein, three iron–sulfur clusters in the iron–sulfur subunit, and quinone-binding sites in the membrane anchors. Sections 3 and 4 describe electron transfer from FAD through the clusters to bound quinone, but do not place heme in that transfer sequence. Section 4 describes heme as coordinated by anchor helices and emphasizes its role in assembly, so the claim that electrons pass through a heme in SdhC is not supported. (LLM, conf=0.88)
- Not checked yetcites [9] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, mutations in subunit SdhB, SdhC, or SdhD are linked to tumorigenesis in the form of autosome-dominant familial paragangliomas and pheochromocytomas (1, 3, 16, 19, 33).”
What the sources say
- Could not verifycites [1] Ackrell B. A. C., 2000, FEBS Lett. sourceExperimental — accuracy not yet measured
The Introduction discusses mutated respiratory-chain complex II in nematodes, and §2 (Flavoprotein subunit) describes a human mutation causing complex II deficiency. Neither passage addresses SDHB, SDHC, or SDHD mutations in familial paragangliomas or pheochromocytomas; searches for those tumors and for familial SDH mutations found no relevant passage. Page numbers were not available in our copy. (LLM, conf=0.75)
- Not checked yetcites [3] source
- Not checked yetcites [16] Douwes Dekker P. B. D., 2003, J. Pathol. source
- Supportedcites [19] source
The Discussion identifies SDHD, SDHC, and SDHB mutations as responsible for familial paraganglioma and describes its inheritance as usually autosomal dominant. The Introduction reports familial pheochromocytoma associated with SDHD and SDHB mutations; the paper's own family had an SDHD mutation and both tumor types. Page numbers were not provided in our copy. (LLM, conf=0.91)
- Partly supportedcites [33] sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) says germline mutations in SDHB, SDHC, and SDHD cause hereditary pheochromocytoma/paraganglioma syndrome, supporting the link to familial tumors. Our copy explicitly calls SDHC-associated paraganglioma autosomal dominant in a reference title, but does not establish that inheritance pattern for all three genes; the Discussion (page unavailable) also notes maternal imprinting in SDHD-associated disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Other studies with diverse model systems also indicate that mutations in complex II can cause increases in ROS production (24, 25, 46, 51, 54).”
What the sources say
- Not checked yetcites [24] source
- Not checked yetcites [25] source
- Supportedcites [46] source
Our copy directly demonstrates the attributed point: the Results section 'Production of Superoxide Anion from Mitochondria Is Elevated in mev-1 Mutants' reports ~2-fold higher superoxide production in mitochondria and SMP from mev-1 animals (which carry a missense mutation in Cyt-1/ceSDHC, the complex II cytochrome b large subunit) versus wild type, and the Discussion summary states mev-1 animals manifest 'superoxide anion overproduction from mitochondrial complex II itself... by the mutation in Cyt-1/ceSDHC subunit.' The hedged 'can cause' in the citing sentence matches the source's claim, and the paper's caveat that the effect is allele-specific (residue 71 missense; more severe mutations may not elevate superoxide) does not contradict a possibility-level statement. The one organism studied (C. elegans) is not overstated by the citing sentence, which pools this with other model systems. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
65 more claims · 2 with their cited sources checked
Create a free account to see all 118 claims and to verify the 43 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 40
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This requires both succinate oxidation by the enzyme succinate dehydrogenase (SDH) and an increase in mitochondrial membrane potential.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has also been reported that defects in SDH B increase ROS production and that ROS enhance the stabilization of HIFα produced by succinate accumulation (Guzy et al., 2007), although the importance of ROS in this setting has been disputed (Lee et al., 2005; Selak et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Guzy et al., 2007
The cited source says what the claim attributes to it.
In the citing paper
“Accumulation of reactive oxygen species, an independent trigger for HIF stabilization, may contribute to this process in some cases of defective SDH or FH (Guzy et al., 2008; Sudarshan et al., 2009).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Guzy et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ MATERIALS AND METHODS
“For dihydroethidium (DHE) and Mito-SOX experiments, cells were treated with the appropriate conditions for 5 to 6 h before the addition of DHE (10 𝛍 M) or Mito-SOX (1 𝛍 M) to the culture medium. Cells were incubated for an additional 1.5 h”
§ RESULTS
“After treatment for 5 h, DHE (1 𝛍 M) was added for an additional hour.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“either polyclonal (SdhA clone 3) or monoclonal (SdhA clones 3C and 3L)”
§ RESULTS
“a monoclonal SdhA shRNA line (SdhA polyclonal line 3C)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ MATERIALS AND METHODS
“Cells were incubated for an additional 1.5 h before being trypsinized and resuspended.”
§ RESULTS
“(H) Cells were treated with the indicated compounds for 5 h, after which Mito-SOX (1 𝛍 M) was added for an additional hour.”
Citations
Cites
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 7×
“In a previous study, the suppression of SdhD expression led to an increase in HIF-1 stabilization, a response that was attributed to the inhibition of PHD by succinate that accumulated as a consequence of the impairment in complex II activity ( 43 ).”
BackgroundMethodInfluentialOxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“A similar model of substrate-mediated PHD inhibition has been described (23, 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
BackgroundChandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
Self-citationMitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 2×
“Previous studies have implicated complex III in the cellular O2-sensing pathway involved in the regulation of HIF- stability during hypoxia (10, 21).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“However, mutations in subunit SdhB, SdhC, or SdhD are linked to tumorigenesis in the form of autosome-dominant familial paragangliomas and pheochromocytomas (1, 3, 16, 19, 33).”
BackgroundMitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Self-citationUbisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria
Turrens, J. F., Alexandre, A., & Lehninger, A. L. (1985) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(85)90293-0 · Cited by 1,214 · cited 1×
“Those interventions would be expected to increase cytosolic superoxide levels, because AA generates superoxide at the outer surface of the inner mitochondrial membrane (50) while p53 induces the expression of a variety of nonmitochondrial oxidase systems (53).”
BackgroundHanson, G. T., Aggeler, R., Oglesbee, D., Cannon, M., Capaldi, R. A., Tsien, R. Y., & Remington, S. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312846200 · Cited by 988 · cited 1×
“Using a novel, engineered, ratiometric fluorescent protein redox sensor (roGFP) (15, 22) expressed in cells by using a recombinant adenovirus, we find that the acute administration of TTFA significantly increases the rate of protein thiol oxidation compared to that induced by 3-NPA, MMA (Fig.”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“A similar model of substrate-mediated PHD inhibition has been described ( 23 , 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
BackgroundArchitecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927 · cited 5×
“... II oxidizes succinate to fumarate and transfers the electrons to ubiquinone through a sequence of steps involving a flavin moiety in SdhA, a set of iron-sulfur clusters in SdhB, a heme group in SdhC, and the ubiquinone binding site in SdhC and SdhD (Fig. 1) (1, 9). When complex II is disrupted at SdhB, SdhC, or Sd…”
BackgroundInfluential
Research works printed but not linked: 1
- Ryan H. E., 2000, Cancer Res., 60, 4010
Cited by
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
“Complex II oxidizes succinate passing electrons to CoQ, but, although the damaged or mutated complex can produce ROS [101,115], it seems that all O 2 •− production during succinate oxidation arises from complex I by RET.”
BackgroundOxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Self-citationWallace, D. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3365 · Cited by 2,404
Mills, E. L., Kelly, B., Logan, A., Costa, A. S. H., Varma, M., Bryant, C. E., Tourlomousis, P., Däbritz, J. H. M., Gottlieb, E., Latorre, I., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.064 · Cited by 2,291
“The B subunit is required for succinate to reduce ubiquinone (Guzy et al., 2008), and its absence will therefore block succinate oxidation.”
Background
Metadata
- Authors
- Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T.
- Affiliations
- Department of Pediatrics, Division of Neonatology
- Northwestern University (US)
- Corresponding author
- Schumacker, Paul T.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2008-01-01
- Volume
- 28
- Issue
- 2
- Pages
- 718-731
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2223429
- OpenAlex
- W2149282639
- Semantic Scholar
- b18b26c88fdc8fd4b5c2258a52b72d9bb98605aa
- Cited by
- 427
- References
- 54
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 29 · 2022: 18 · 2021: 30 · 2020: 31 · 2019: 22 · 2018: 26 · 2017: 18 · 2016: 23 · 2015: 24 · 2014: 32 · 2013: 22 · 2012: 29
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL 32646, HL079650, R01HL035440, R01HL079650, HL35440)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- succinate dehydrogenase, SDHB, SDHA, reactive oxygen species, hypoxia-inducible factor alpha, HIF-1α, HIF-2α, tumor suppressor, carcinogenesis, cell proliferation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Iron-Sulfur Proteins, Male, Mice, Nude, Neoplasm Transplantation, Protein Binding, Succinate Dehydrogenase, Signal Transduction, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Reactive Oxygen Species, Protein Subunits, RNA Interference, Electron Transport Complex II, Cell Line, Tumor, Cell Proliferation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis. https://app.cochat.ai/papers/10.1128/mcb.01338-07
- The paper
- Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T. (2008). Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis. Molecular and Cellular Biology. https://doi.org/10.1128/mcb.01338-07
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.